Registered title, quoted from ClinicalTrials.gov
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Shenzhen University General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT05620732, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 9
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (9 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);
Inclusion criterion 3
According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;
Exclusion criterion 4
Grade 3 hypertension and poor blood pressure control after drug treatment;
Exclusion criterion 7
ECOG score is 0-2;
Inclusion criterion 9
The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of central granulocyte ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ;
Exclusion criterion 2
The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;
Exclusion criterion 3
According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;
Inclusion criterion 4
HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;
Exclusion criterion 13
Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;
Exclusion criterion 16
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05620732, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-75 (≥ 18, ≤ 75), regardless of gender;
- Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;
- Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);
- According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;
- Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;
- Subjects must have received the first and second line standard treatment scheme;
- The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and/or surgery/immunosuppressant at the checkpoint, or refuse surgical resection
- Within 2 weeks before cell therapy, no antibody drugs were used;
- ECOG score is 0-2;
- The subjects had no contraindication for peripheral blood collection;
- The expected survival period is more than 3 months.
Exclusion Criteria:
- People who have a history of allergy to any component in cell products;
- The following conditions occur in blood routine examination: WBC ≤ 1 × 109/L, absolute value of central granulocyte ANC ≤ 0.5 × 109/L, absolute value of lymphocyte ALC ≤ 0.5 × 109/L , PLT≦25 × 109/L ;
- The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg/dl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg/dl;
- According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)<50% by echocardiography;
- Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;
- Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;
- Grade 3 hypertension and poor blood pressure control after drug treatment;
- Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;
- Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;
- There is uncontrolled active infection;
- Have used any CAR-T cell product or other genetically modified T cell therapy before;
- Live vaccine inoculation within 4 weeks before enrollment;
- HIV, HBV, HCV and TPPA/RPR positive persons, and HBV carriers;
- Subjects have a history of alcohol abuse, drug abuse or mental illness;
- Subjects have participated in any other clinical research within 3 months before joining this clinical research;
- Female subjects have any of the following conditions: a) are in pregnancy/lactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;
- The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study
Quoted from ClinicalTrials.gov, NCT05620732, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT05620732, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.